-
Views
-
Cite
Cite
Maria Pia Sormani, Heinz Wiendl, Xavier Montalban, Jiwon Oh, Rethinking multiple sclerosis therapy beyond clinical phenotypes, Brain, Volume 149, Issue 11, November 2026, Pages 3703–3707, https://doi.org/10.1093/brain/awag273
Close - Share Icon Share
Extract
When biology and clinical labels no longer align, drug development risks missing meaningful therapeutic effects. Multiple sclerosis trials should move beyond phenotype-based classifications toward mechanism-based evaluation.
Multiple sclerosis (MS) is being increasingly recognized as a biological continuum rather than a set of discrete clinical phenotypes. Despite advances in diagnostic criteria and data-driven reclassification efforts, clinical trial design and regulatory frameworks continue to rely on traditional course descriptors such as relapsing–remitting, secondary progressive and primary progressive MS. Recent phase 3 trials of Bruton’s tyrosine kinase (BTK) inhibitors illustrate the limitations of this phenotype-based approach. Across relapsing and progressive populations, BTK inhibition demonstrates consistent effects on disability accumulation and neurodegeneration that are not fully explained by suppression of acute inflammatory activity. Apparent discrepancies in statistical significance between trials are compatible with a shared underlying biological effect. These findings support a mechanism-centred framework for evaluating therapies targeting progression independent of relapse activity. Aligning trial design and regulatory decision-making with contemporary understanding of MS biology may improve therapeutic development and ensure equitable access to effective treatments across the disease spectrum.